Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
QNQuince Therapeutics, Inc. logo

Quince Therapeutics, Inc. (QNCX)

NASDAQ Global Select · Currency in USD
$31.73 ▲ +2.37 (+8.07%)
At close: Oct 9, 4:00 PM ET. Market closed.
$32.00 ▲ +0.27 (+0.85%)
After hours: Oct 9, 7:40 PM ET

Summary

Previous Close
$29.36
Open
$30.50
Day's Range
$29.84 – $37.00
52 Week Range
$15.10 – $910.00
Volume
138,744
Avg. Volume
56,479
Market Cap
$8.83M
Beta (5Y Monthly)
1.33
PE Ratio (TTM)
--
EPS (TTM)
-$15.08
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$70.00

Profile: Quince Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
38
CEO
Dirk Thye

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$1.39
DateEst.Actual
Aug 14, 2026-$28.02-$12.31Beat
May 12, 2026-$26.00$75.60Beat
Apr 6, 2026-$3.59-$3.50Beat
Nov 12, 2025-$40.00-$50.00Miss
Aug 11, 2025-$56.00-$68.00Miss
May 13, 2025-$48.00-$68.00Miss

Analyst view

Consensus price target
$70.00 ▲ +120.6%
Range $68.00 – $72.00
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on QNCX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.